Steven Cohen Neurocrine Biosciences Inc Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $72.3 Million - $79.7 Million	-554,544 Reduced 39.84%	837,426 $115 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $126 Million - $157 Million	-1,186,158 Reduced 46.01%	1,391,970 $183 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $232 Million - $289 Million	2,466,770 Added 2215.17%	2,578,128 $290 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $9.97 Million - $11.7 Million	111,358 New	111,358 $10.5 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $6.62 Million - $8.75 Million	87,402 Added 15.12%	665,300 $64.9 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $3.63 Million - $4.75 Million	50,124 Added 9.5%	577,898 $54.2 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $30.2 Million - $40.2 Million	378,826 Added 254.33%	527,774 $45 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $12.8 Million - $14.8 Million	148,948 New	148,948 $14.3 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $1.99 Million - $2.71 Million	-22,679 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $1.97 Million - $2.46 Million	22,679 New	22,679 $2.17 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $1.54 Million - $2.36 Million	-18,124 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $3.15 Million - $4.76 Million	-41,879 Reduced 69.79%	18,124 $1.57 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $2.64 Million - $3.61 Million	30,459 Added 103.1%	60,003 $6.45 Million
Q3 2019 Nov 15, 2019	SELL	$83.82 - $101.5 $91.8 Million - $111 Million	-1,095,140 Reduced 97.37%	29,544 $2.66 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $53.2 Million - $67.2 Million	735,992 Added 189.35%	1,124,684 $95 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $26.9 Million - $35.6 Million	388,692 New	388,692 $34.2 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $4.44 Million - $8.08 Million	-65,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $82.2 Million - $105 Million	-830,900 Reduced 92.74%	65,000 $7.99 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $61.8 Million - $87 Million	820,900 Added 1094.53%	895,900 $88 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $5.69 Million - $6.93 Million	75,000 New	75,000 $6.22 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $16.2 Million - $21.4 Million	-276,322 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $13.3 Million - $16.9 Million	276,322	276,322 $16.9 Million

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$1.92 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.35 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$697 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$349 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$252 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account